Michael Pacold

217 posts

Michael Pacold banner
Michael Pacold

Michael Pacold

@MichaelPacold

Assistant Professor @nyulangone, @NYULH_RadOnc. Interested in chemical biology applied to metabolism. Tweets are my own.

Katılım Haziran 2017
186 Takip Edilen445 Takipçiler
Juanma Schvartzman
Juanma Schvartzman@Schvartzman_JM·
@MichaelPacold @SillitoeLab Congrats on an incredibly inspiring story. This work epitomizes the role of the physician scientist in academic research, taking fundamental understanding of a process and immediately recognizing (and realizing) clinical implications
English
1
0
2
56
Michael Pacold
Michael Pacold@MichaelPacold·
Just published: nature.com/articles/s4158… Coenzyme Q10 (CoQ10) is critical for mitochondrial function and for controlling reactive oxygen species damage to biological membranes. Because CoQ10 is poorly bioavailable, new approaches are needed to promote CoQ10 synthesis. In our latest paper @Nature, we use CoQ10 headgroup intermediates to restore CoQ10 synthesis in mouse models of HPDL encephalopathy, a rare pediatric neurodevelopmental disease driven by loss of CoQ10 headgroup synthesis. We also use CoQ10 headgroup intermediates to modify the course of this same disease in a patient. Primary CoQ10 deficiencies are rare mitochondrial disorders caused by loss of function of the enzymes that make CoQ10. The neurological symptoms of these diseases respond poorly to CoQ10, likely due to poor bioavailability of this molecule. The newest primary CoQ10 deficiency is HPDL encephalopathy, which is due to loss-of-function variants in the enzyme 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). A few years ago, we discovered that HPDL carries out the first committed step of the mammalian CoQ10 headgroup synthesis pathway, in a study led by Robert Banh @BanhLab: nature.com/articles/s4158… We found that the enzyme HPDL makes 4-hydroxymandelate (4-HMA), the first committed precursor of 4-hydroxybenzoate (4-HB), which generates the CoQ10 headgroup. Patients with HPDL encephalopathy develop spastic paresis, and in severe cases, seizures, neurodevelopmental delay, and death. Mice lacking Hpdl recapitulate these symptoms and die by 15 days after birth. We find that treatment of Hpdl-/- mice with 4-HMA or 4-HB significantly improves the survival of mice from days to years. We treated a single patient with loss-of-function HPDL variants with 4-HB, with dramatic improvement in his symptoms. Thanks to co-authors including Robert Banh @BanhLab and Sota Kuno @kuno_sota, editors George Caputa @curiousdrgeorge and Victoria Aranda @mvicaracal, and reviewers including @RutterLab and everyone at @NYULangone @nyugrossman who made this work possible! Many thanks to our collaborators, Roy Sillitoe @BCMHouston / @TexasChildrens and Alex Joyner @MSKCancerCenter. Grateful for funding from @DamonRunyon @PershingSqFdn @psscra @MindPrize @AmericanCancer @HarringtonDI_UH @OHRareDisease @NIH.
English
19
32
133
16.1K
Michael Pacold
Michael Pacold@MichaelPacold·
@RobertoZoncu Thanks, Roberto! Now need to see if we can bring this to more patients...
English
0
0
0
37
Walter W. Chen, MD, PhD
Walter W. Chen, MD, PhD@WalterWChen1·
Our paper on discovering a new paradigm in peroxisome biogenesis and PEX39 (1st human peroxisomal biogenesis protein found in > 20 yr) is out in @NatureCellBio! Wonderful, equal collab with Tony Rodrigues, @dwendscheck, Jorge Azevedo, @warscheidlab #ref-CR49" target="_blank" rel="nofollow noopener">nature.com/articles/s4155…
Walter W. Chen, MD, PhD@WalterWChen1

V happy to share my work in @RJDLab @CRI_UTSW from past 2 yr! In equal collab with Tony Rodrigues, @dwendscheck, Jorge Azevedo’s lab, @warscheidlab, we have discovered PEX39, the first human peroxisomal biogenesis protein (peroxin/PEX) found in > 20 yr! biorxiv.org/content/10.110…🧵

English
22
28
160
20.5K
Raghu Chivukula, MD PhD 🫁🧬🧠
Raghu Chivukula, MD PhD 🫁🧬🧠@chivukula_raghu·
Why do some genetic mutations devastate specific tissues while sparing others? We explore this question in GGC repeat disorders, revealing a mechanism linking protein aggregation to tRNA splicing failure in the brain. 🧵 on our new paper in Science: 🔗 science.org/doi/10.1126/sc…
English
18
52
197
30.8K
Michael Pacold
Michael Pacold@MichaelPacold·
@bealelab Thank you, Rupert! Lots to do and very much enjoying it.
English
0
0
1
112
Luis Carlos López
Luis Carlos López@luiscaloga·
Congrats to @MichaelPacold for showing the therapeutic potential of 4HB in HPDL deficiency @Nature. Last year, we showed similar effects of 4HB in Coq2 models (@CellReports). More exciting news are coming soon!
English
1
0
2
156
David M. Sabatini
David M. Sabatini@DMSabatini·
Congratulations @MichaelPacold and team. A wonderful example of basic science directly and quickly impacting disease therapy.
Michael Pacold@MichaelPacold

Just published: nature.com/articles/s4158… Coenzyme Q10 (CoQ10) is critical for mitochondrial function and for controlling reactive oxygen species damage to biological membranes. Because CoQ10 is poorly bioavailable, new approaches are needed to promote CoQ10 synthesis. In our latest paper @Nature, we use CoQ10 headgroup intermediates to restore CoQ10 synthesis in mouse models of HPDL encephalopathy, a rare pediatric neurodevelopmental disease driven by loss of CoQ10 headgroup synthesis. We also use CoQ10 headgroup intermediates to modify the course of this same disease in a patient. Primary CoQ10 deficiencies are rare mitochondrial disorders caused by loss of function of the enzymes that make CoQ10. The neurological symptoms of these diseases respond poorly to CoQ10, likely due to poor bioavailability of this molecule. The newest primary CoQ10 deficiency is HPDL encephalopathy, which is due to loss-of-function variants in the enzyme 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). A few years ago, we discovered that HPDL carries out the first committed step of the mammalian CoQ10 headgroup synthesis pathway, in a study led by Robert Banh @BanhLab: nature.com/articles/s4158… We found that the enzyme HPDL makes 4-hydroxymandelate (4-HMA), the first committed precursor of 4-hydroxybenzoate (4-HB), which generates the CoQ10 headgroup. Patients with HPDL encephalopathy develop spastic paresis, and in severe cases, seizures, neurodevelopmental delay, and death. Mice lacking Hpdl recapitulate these symptoms and die by 15 days after birth. We find that treatment of Hpdl-/- mice with 4-HMA or 4-HB significantly improves the survival of mice from days to years. We treated a single patient with loss-of-function HPDL variants with 4-HB, with dramatic improvement in his symptoms. Thanks to co-authors including Robert Banh @BanhLab and Sota Kuno @kuno_sota, editors George Caputa @curiousdrgeorge and Victoria Aranda @mvicaracal, and reviewers including @RutterLab and everyone at @NYULangone @nyugrossman who made this work possible! Many thanks to our collaborators, Roy Sillitoe @BCMHouston / @TexasChildrens and Alex Joyner @MSKCancerCenter. Grateful for funding from @DamonRunyon @PershingSqFdn @psscra @MindPrize @AmericanCancer @HarringtonDI_UH @OHRareDisease @NIH.

English
1
0
25
3.9K